Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Standard Biotools (LAB) Net Margin (2016 - 2025)

Standard Biotools (LAB) has disclosed Net Margin for 16 consecutive years, with 294.12% as the latest value for Q3 2025.

  • On a quarterly basis, Net Margin rose 1539.0% to 294.12% in Q3 2025 year-over-year; TTM through Sep 2025 was 60.89%, a 909.0% decrease, with the full-year FY2024 number at 106.0%, down 3580.0% from a year prior.
  • Net Margin was 294.12% for Q3 2025 at Standard Biotools, up from 153.75% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 566.95% in Q4 2022 to a low of 338.46% in Q2 2022.
  • A 5-year average of 21.01% and a median of 61.59% in 2023 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: surged 59159bps in 2022, then plummeted -51832bps in 2023.
  • Standard Biotools' Net Margin stood at 24.64% in 2021, then surged by 2401bps to 566.95% in 2022, then plummeted by -91bps to 48.63% in 2023, then plummeted by -165bps to 31.49% in 2024, then skyrocketed by 1034bps to 294.12% in 2025.
  • Per Business Quant, the three most recent readings for LAB's Net Margin are 294.12% (Q3 2025), 153.75% (Q2 2025), and 80.45% (Q1 2025).